We are live on
!
Find out more
Axa Portfolio holdings
AUM
$91.9M
1-Year Est. Return
27.41%
This Fund
S&P 500
This Quarter
Est. Return
+2.56%
1 Year Est. Return
+27.41%
3 Year Est. Return
+100.68%
5 Year Est. Return
+129.89%
10 Year Est. Return
+554.73%
AUM
$23B
AUM Growth
+$654M
(+2.9%)
Cap. Flow
+$6.71M
Cap. Flow
% of AUM
0.03%
Top 10 Holdings %
Top 10 Hldgs %
15.45%
Holding
1,532
New
151
Increased
540
Reduced
484
Closed
141
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verizon
VZ
|
+$284M |
| 2 |
Deutsche Bank
DB
|
+$159M |
| 3 |
Norfolk Southern
NSC
|
+$108M |
| 4 |
HP
HPQ
|
+$92.2M |
| 5 |
DD
Du Pont De Nemours E I
DD
|
+$80.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$161M |
| 2 |
Ford
F
|
+$87.9M |
| 3 |
Whirlpool
WHR
|
+$74M |
| 4 |
PNC Financial Services
PNC
|
+$72.9M |
| 5 |
Eastman Chemical
EMN
|
+$72.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.62% |
| 2 | Technology | 14.22% |
| 3 | Financials | 13.17% |
| 4 | Industrials | 11.49% |
| 5 | Energy | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITG
876
DELISTED
Investment Technology Group Inc
ITG
| $1.11M | ﹤0.01% |
55,180
-2,200
| -4% | -$39.7K |
|
877
Emergent Biosolutions
EBS
$326M
| $1.1M | ﹤0.01% |
43,400
-5,200
| -11% | -$131K |
|
|
FLG
878
Flagstar Bank National Association
FLG
$5.33B
| $1.1M | ﹤0.01% |
22,733
-19,234
| -46% | -$935K |
|
879
Acadia Pharmaceuticals
ACAD
$4.61B
| $1.08M | ﹤0.01% |
44,538
+2,319
| +5% | +$58.7K |
|
880
Ralph Lauren
RL
$20B
| $1.07M | ﹤0.01% |
6,681
-6,200
| -48% | -$999K |
|
|
MSF
881
DELISTED
Morgan Stanley Emerging Mkts Fd
MSF
| $1.07M | ﹤0.01% |
70,000
| – | – |
|
882
National Health Investors
NHI
$3.4B
| $1.06M | ﹤0.01% |
17,500
| – | – |
|
883
Unisys
UIS
$183M
| $1.05M | ﹤0.01% |
+34,600
| New | +$1.12M |
|
884
Koppers
KOP
$866M
| $1.05M | ﹤0.01% |
+25,400
| New | +$1.04M |
|
|
AMRI
885
DELISTED
Albany Molecular Research Inc
AMRI
| $1.03M | ﹤0.01% |
55,600
-11,300
| -17% | -$156K |
|
886
KKR & Co
KKR
$89.8B
| $1.03M | ﹤0.01% |
45,175
| – | – |
|
|
POM
887
DELISTED
PEPCO HOLDINGS, INC.
POM
| $1.03M | ﹤0.01% |
50,170
+15,791
| +46% | +$311K |
|
888
Park-Ohio Holdings
PKOH
$652M
| $1.03M | ﹤0.01% |
18,270
-5,800
| -24% | -$296K |
|
889
iShares MSCI Israel ETF
EIS
$895M
| $1.02M | ﹤0.01% |
19,400
| – | – |
|
890
Invesco DB Commodity Index Tracking Fund
DBC
$2B
| $1.02M | ﹤0.01% |
39,141
+7,116
| +22% | +$182K |
|
891
Ultragenyx Pharmaceutical
RARE
$1.29B
| $1.02M | ﹤0.01% |
+20,852
| New | +$1.07M |
|
892
Vanguard Energy ETF
VDE
$11.2B
| $1.01M | ﹤0.01% |
7,900
+940
| +14% | +$116K |
|
|
REMY
893
DELISTED
REMY INTL INC NEW COMMON
REMY
| $1.01M | ﹤0.01% |
42,754
+15,046
| +54% | +$325K |
|
894
Oneok
OKE
$59.7B
| $1M | ﹤0.01% |
16,901
-1,033
| -6% | -$60.4K |
|
|
AHT
895
Ashford Hospitality Trust
AHT
$19.3M
| $1M | ﹤0.01% |
95
-14
| -13% | -$129K |
|
896
BancFirst
BANF
$3.73B
| $985K | ﹤0.01% |
34,800
+19,054
| +121% | +$524K |
|
|
HA
897
DELISTED
Hawaiian Holdings, Inc.
HA
| $972K | ﹤0.01% |
69,600
-45,300
| -39% | -$529K |
|
|
NY
898
DELISTED
ISHARES NYSE 100 ETF
NY
| $969K | ﹤0.01% |
11,330
| – | – |
|
899
iShares US Energy ETF
IYE
$1.91B
| $964K | ﹤0.01% |
18,900
+1,110
| +6% | +$54.6K |
|
|
RJET
900
DELISTED
REPUBLIC AWYS HLDGS INC
RJET
| $964K | ﹤0.01% |
105,500
+16,400
| +18% | +$159K |
|
Similar funds
VI
FA
PBCM
CCAM
GBA
AWP
HI
DCA
Axa's Q1 2014 Portfolio in Review
As of Q1 2014, Axa held 1,532 positions worth $23B, up 2.9% from $22.3B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Axa's Q1 2014 filing shows 151 new, 540 increased, 484 reduced and 141 closed positions. Its largest new stake was Celanese: 949,936 shares worth $52.7M. The largest sale was Eli Lilly, an estimated $161M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 16% a quarter earlier, followed by Technology and Financials.
- Axa's largest Q1 2014 buy was Celanese: 949,936 shares worth $52.7M.
- Axa added most to Verizon in Q1 2014, an estimated $284M increase.
- Axa's biggest Q1 2014 reduction was Eli Lilly, cutting an estimated $161M.
- Axa fully exited Avon Products, Inc. in Q1 2014, selling an estimated $53.7M.
- Axa's ten largest holdings make up 15% of its $23B portfolio in Q1 2014.
- Axa opened 151 new positions and closed 141 in Q1 2014.
- Axa's portfolio value rose 2.9% quarter-over-quarter to $23B.
Based on Axa's 13F filing for Q1 2014, filed 13 May 2014.